Clarus Therapeutics Holdings, Inc. (CRXTQ)

USD 0.0

(0.0%)

EBITDA Summary of Clarus Therapeutics Holdings, Inc.

  • Clarus Therapeutics Holdings, Inc.'s latest annual EBITDA in 2021 was -39.7 Million USD , up 15.76% from previous year.
  • Clarus Therapeutics Holdings, Inc.'s latest quarterly EBITDA in 2022 Q2 was -10.64 Million USD , up 21.38% from previous quarter.
  • Clarus Therapeutics Holdings, Inc. reported an annual EBITDA of -47.13 Million USD in 2020, down 0.0% from previous year.
  • Clarus Therapeutics Holdings, Inc. reported a quarterly EBITDA of -13.54 Million USD for 2022 Q1, down 0.0% from previous quarter.
  • Clarus Therapeutics Holdings, Inc. reported a quarterly EBITDA of N/A for 2021 FY, up 15.76% from previous quarter.

Annual EBITDA Chart of Clarus Therapeutics Holdings, Inc. (2021 - 2020)

Historical Annual EBITDA of Clarus Therapeutics Holdings, Inc. (2021 - 2020)

Year EBITDA EBITDA Growth
2021 -39.7 Million USD 15.76%
2020 -47.13 Million USD 0.0%

Peer EBITDA Comparison of Clarus Therapeutics Holdings, Inc.

Name EBITDA EBITDA Difference
AstraZeneca PLC 13.28 Billion USD 100.299%
Bristol-Myers Squibb Company PFD CONV 2 19.41 Billion USD 100.204%
CSPC Pharmaceutical Group Limited 1.14 Billion USD 103.458%
Novartis AG 19.51 Billion USD 100.203%
PT Kalbe Farma Tbk. 288.13 Million USD 113.78%